The results indicate a 90% progression-free survival rate at six months for patients with metastatic pancreatic ductal adenocarcinoma (PDAC).Tango Therapeutics Phase 1/2 Data Drives TNGX Premarket MoveThe initial data from the trial showed that 92% of patients treated with the vopimetostat and daraxonrasib combination achieved an objective response, with the company planning to advance this combination into Phase 3 development for first-line treatment of MTAP-deleted pancreatic cancer.The news comes as the company aims to provide a chemotherapy-free option for patients, which could significantly reshape treatment protocols for this aggressive disease.The data showed a 6-month progression-free survival of 90%, with a 100% disease control rate.For the opimetostat plus zoldonrasib combination, the biotechnology company reported an objective response rate of 52%, 6-month progression-free survival of 74%, and 96% disease control rate.TNGX Technical Outlook: Bullish Trend With Momentum CoolingTango Therapeutics has demonstrated remarkable performance over the past year, with a 12-month gain of 386.06%. However, the stock is currently trading 60.9% above its 20-day simple moving average of $21.75, indicating a strong bullish trend.The MACD is below its signal line, suggesting that upside momentum may be fading unless it can reclaim that baseline.Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $31.78. Recent analyst moves include: